Organon & Co | OGN - Assets


Organon & Co reported $13.55B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Celltrion KRW 21.08T 530.63B Sep/2025
Cspc Pharmaceutical CNY 46.7B 695.56M Dec/2025
Deva Holding AS TRY 12.93B 1.83B Sep/2023
Dianthus Therapeutics USD 530.92M 46.52M Dec/2025
Divis Laboratories Ltd INR 181.51B 12.19B Sep/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Kangmei Pharma CNY 13.68B 38.19M Sep/2025
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Laboratorios Farma EUR 799.88M 99.95M Dec/2023
Malin Corporation EUR 198.5M 70.1M Dec/2024
Medical Developments International AUD 63.57M 2.83M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Neuren Pharmaceuticals AUD 342.86M 11.61M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Organigram Holdings CAD 530.67M 31.54M Dec/2025
Organon & Co USD 13.55B 52M Sep/2025
Ovoca Bio EUR 1.66M 9.75M Jun/2025
Pharma Mar EUR 395.08M 53.42M Dec/2025
Qiagen NV USD 6.3B 257.54M Dec/2025
Sartorius EUR 9.61B 413.4M Sep/2025
Sino Biopharmaceutical CNY 74.89B 9.49B Jun/2025
Tilray USD 2.1B 15.95M Sep/2025
Zealand Pharma A/S 15.95B 848.45M Dec/2025